Boston Scientific (BSX) Fell Amid Concerns Over Growth Durability

2 days ago 9

Soumya Eswaran

Thu, May 14, 2026 astatine 9:26 AM CDT 3 min read

Aristotle Capital Management, LLC, an concern absorption company, released its “Core Equity Fund” first-quarter 2026 capitalist letter. A transcript of the missive tin beryllium downloaded here. During the archetypal quarter, the U.S. equity marketplace declined, with the S&P 500 Index falling by 4.33%. The fixed-income assemblage besides saw a downturn; the Bloomberg U.S. Aggregate Bond Index fell by 0.05%. In the quarter, the Fund (Class I-2) posted a full instrumentality of -4.45%, compared to the S&P 500 Index’s -4.33% return. The Fund’s underperformance successful the 4th was driven by the allocation effect, portion information enactment contributed positively. In this environment, the Fund continues to absorption connected companies experiencing secular tailwinds oregon robust product-driven cycles. In addition, delight cheque the Fund’s apical 5 holdings to cognize its champion picks successful 2026.

In its first-quarter 2026 capitalist letter, Aristotle Core Equity Fund highlighted stocks specified arsenic Boston Scientific Corporation (NYSE:BSX). Boston Scientific Corporation (NYSE:BSX) is simply a aesculapian exertion institution that manufactures and markets aesculapian devices for usage successful assorted interventional aesculapian specialties. On May 13, 2026, Boston Scientific Corporation (NYSE:BSX) closed astatine $53.06 per share. One-month instrumentality of Boston Scientific Corporation (NYSE:BSX) was -16.34%, and its shares mislaid 49.40% implicit the past 52 weeks. Boston Scientific Corporation (NYSE:BSX) has a marketplace capitalization of $78.87 billion.

Aristotle Core Equity Fund stated the pursuing regarding Boston Scientific Corporation (NYSE:BSX) successful its Q1 2026 capitalist letter:

"Boston Scientific Corporation (NYSE:BSX) detracted from show successful the archetypal 4th arsenic investors debated the durability of the outsized maturation the institution has reported successful electrophysiology (EP) and the Watchman near atrial appendage closure device. Boston reported affirmative results toward the extremity of the 4th connected the CHAMPION-AF proceedings comparing the Watchman instrumentality to modular blood-thinner attraction successful changeable prevention; however, the results inactive fell abbreviated of marketplace expectations. Boston volition request to amusement a rebound successful EP results erstwhile it reports archetypal 4th net to quell marketplace concerns."

Was Jim Cramer Right About Boston Scientific Corporation (BSX)?

Boston Scientific Corporation (NYSE:BSX) is not connected our database of 40 Most Popular Stocks Among Hedge Funds Heading Into 2026. According to our database, 110 hedge money portfolios held Boston Scientific Corporation (NYSE:BSX) astatine the extremity of the 4th quarter, up from 102 successful the erstwhile quarter. In the archetypal 4th of 2026, Boston Scientific Corporation (NYSE:BSX) delivered consolidated revenue of $5.203 billion, representing 11.6% year-over-year maturation compared to Q1 2025. While we admit the imaginable of Boston Scientific Corporation (NYSE:BSX) arsenic an investment, we judge definite AI stocks connection greater upside imaginable and transportation little downside risk. If you're looking for an highly undervalued AI banal that besides stands to payment importantly from Trump-era tariffs and the onshoring trend, spot our escaped study connected the best short-term AI stock.

Read Entire Article